Bloomberg’s emerging-market technology index fell into a bear market in July 2026, with SK Hynix shares dropping 40% and Samsung Electronics down 29% over the month [1, 2, 3]. Meanwhile, at least 10 Chinese pharmaceutical stocks posted double-digit gains, making healthcare the best-performing sector in Bloomberg’s emerging-market benchmark [1, 2, 3].
Chinese biotech firms have attracted investor interest as concerns grow over valuation and concentration in AI stocks. Nelson Yu, head of equities at AllianceBernstein in New York, said, "As investors become increasingly concerned about concentration in AI and AI-adjacent investments, healthcare is increasingly being viewed as an attractive way to gain exposure to innovation, secular growth and profitability while remaining largely uncorrelated to the AI trade" [1, 3]. Similar comments were made by a senior AllianceBernstein executive in Chinese markets [2].
Key Chinese drugmakers are expanding globally by licensing novel drug candidates to multinational pharmaceutical companies, reversing previous trends where Western firms led innovation [1, 2, 3]. CSPC Innovation Pharmaceutical exemplifies this shift. The company’s shares rose 52% in July 2026 after it announced a licensing deal with AstraZeneca. The UK drugmaker may pay up to US$1.8 billion for global rights to CSPC’s RNA-based treatments for kidney disease [1, 2, 3].
This licensing arrangement highlights growing intellectual property flows from China to Western drugmakers. The trend reflects increased confidence in Chinese biotech innovation and a growing global footprint [1, 2, 3].
Investors continue rotating capital from AI to healthcare as they seek diverse innovation-driven growth opportunities within emerging markets. The developments in July mark a concrete shift in emerging-market technology trade dynamics. Reporting will continue as further licensing deals and stock movements unfold in the coming months.
